Table 2.
Pharmacokinetic Properties of SIV Env RhmAbs across Study Groups
| ITS09.01-LS | ITS102.01-LS | ITS103.01-LS | ITS113.01-LS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Cmax (μg ml−1) | Ctrough (μg ml−1) | Half-life (days) | Cmax (μg ml−1) | Ctrough (μg ml−1) | Half-life (days) | Cmax (μg ml−1) | Ctrough (μg ml−1) | Half-life (days) | Cmax (μg ml−1) | Ctrough (μg ml−1) | Half-life (days) |
| RhmAb | 180 | 36 | 7.9 | 215 | 44 | 6.1 | 250 | 33 | 7.2 | 944 | 176 | 5.6 |
| RhmAb + AZD5582 | 315 | 64 | 8.6 | 448 | 25 | 5.8 | 348 | 6 | 4.0 | 832 | 94 | 10.1 |
| RhmAb + AZD5582 + N-803 | 170 | 8 | 7.8 | 184 | 1 | 5.8 | 179 | 1 | 3.1 | 877 | 49 | 5.7 |